Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Intermittent self-catheterisation in MS.
Safety Study of Interferon Beta-1a for Acute Stroke
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Pharmacology and therapeutic potential of interferons.
American Academy of Neurology Annual Meeting
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Dilantin
Alemtuzumab benefits hard-to-treat MS patients
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.

Pages

« first
‹ previous
…
103
104
105
106
107
108
109
110
111
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By